Mariana Babayeva MD, PhD is an Associate Professor at Touro College of Pharmacy, New York, NY. In addition to her role at Touro, Dr. Babayeva is also an Adjunct Professor at Rockefeller University and Visiting Scientist at Arnold and Marie Schwartz School of Pharmacy of LIU. Dr. Babayeva has over 14 years of experience in clinical practice. She is recognized for her expertise in the pharmacokinetics and the use of animal and organ models. Dr. Babayeva has conducted several international research projects. Dr. Babayeva has been published in peer-reviewed journals and serving as an editorial board member of repute.
Emmanuel O. Akala, R. Ph., Ph.D. is a Professor of Pharmaceutics, Chair, Howard University Institutional Animal Care and Use Committee (IACUC) and Director, Laboratory for Nanomedicine, Drug Delivery, and Pharmaceutical & Biopharmaceutical Drug Products Design. His training is cosmopolitan and his curriculum vitae (CV) provides details of his professional training as a pharmacist and an immunization pharmacist (registered in Utah, Maryland, Washington DC and in Nigeria), a pharmacy professor, and a research scientist with bias for conventional and novel drug delivery systems. Professor Akala received B. Pharm. (Hons) degree and M.Sc. (Pharmaceutics) degree at The University of Ife (Now Obafemi Awolowo University), Ile-Ife, Nigeria and Ph.D. degree in Pharmaceutics at The University of Manchester, England (as a Commonwealth Scholar). He was a DAAD Fellow at the Institute of Biopharmaceutics and Pharmaceutical Technology, University of Munster, Germany, and an NIH Postdoctoral Fellow in Pharmaceutics and Bioengineering at The University of Utah, USA. He has worked as a pharmacist in Nigeria and USA, and as a Lecturer and Senior Lecturer in Pharmaceutics in Nigeria, as a Teaching Assistant in England, as a Laboratory Instructor and Research Associate in USA and Germany and as an Assistant Professor, Associate Professor and Professor of Pharmaceutics in USA. Professor Akala has established a very active research group with capability for the design and development of conventional and novel drug products/drug delivery systems. His research focus, at the moment, is on nanotechnology platform for the treatment of cancer and HIV/AIDS with the applications of quality by design (QbD), statistical experimental design, computer optimization, and process analytical technology in his research efforts. At Howard University, he has obtained more than ten million dollars in research grants. His current research grant funding is as follows: (1) NIH/NCI (Akala (PI): Novel Nanotechnology Platform for Breast Cancer Treatment ($1,132,500:00: 2015 -2018). (2) NIH/NIAID (Akala (PI):The District of Columbia Center for AIDS Research: Targeting Drug (ARV) Loaded Multifunctional Nanoparticles to M Cells Overlaying GALT (HIV-1 Reservoir) ($600,000:00: 2011 -2016). (3). U.S. ? Russian University Research Competition (CRDF Global - Peace and Prosperity Through Science Collaboration PI: ($110,000) (June 1, 2015 – May 31, 2017). Professor Akala holds three patents. He has numerous research publications in peer reviewed journals and several conference proceedings and abstracts. In the HU College of Pharmacy, Professor Akala was the Chairman of the Practice and Physical Facilities Sub-Committee (twice) during the reaccreditation programs. He initiated the survey of our external preceptors to substantiate the contents of our accreditation dossier. He was the Chairman of the Admission, Recruitment and Retention Committee. He initiated changing of our maths admission questions every year; we continue the tradition till today. He has served and/or chaired varied and diverse committees in his Department, HU College of Pharmacy, Howard University, and nationally & internationally. Over the years, Professor Akala has taught several Pharm. D. courses and has developed and taught several Ph.D. courses and mentored several Doctor of Pharmacy students. He has directed the research work of eight M.S. students, four Ph.D. students, eight postdoctoral fellows, several Pharm. D., B.S., and high school students and four pharmacy students from different Universities in Brazil (Brazil Scientific Mobility Program). His research endeavors have been characterized by wide interactions and associations (interdisciplinary approach to research) at Howard University, within USA and in Germany, UK and Demark. Professor Akala received the 2013 Distinguished Howard University College of Pharmacy Alumni Award, the 2013 Top Reviewer Award in the Journal of Pharmaceutical Sciences, the 2013 Top Reviewer Award in the Journal of Nanomedicine, the 2014 AACR Minority-Serving Institution Faculty Scholar in Cancer Research Award, and the 2016 Washington DC Pharmacy Association NASPA Excellence in Innovation Award. Professor Akala has been serving as a member of the Advisory Group of the Center for Pharmaceutical Advancement and Training of the United States Pharmacopeia since 2013. He was appointed, in 2015, a member of the USP (the General Chapters-Dosage Forms USP’s Expert Committee). USP Expert Committees are responsible for developing and revising USP standards that comprise its compendia: the USP and the NF, USP Compounding Compendium, Herbal Medicines Compendium, Dietary Supplements Compendium, and Food Chemicals Codex.
Steen Honoré Hansen obtained his degree in pharmacy from The Royal Danish School of Pharmacy in Copenhagen, Denmark. After graduation he worked for four years in a department for analytical chemical research at Dumex Ltd, Copenhagen. In 1975 he came to the Royal Danish School of Pharmacy, Dept of Organic Chemistry as an assistant professor. In 1977 he became an associate professor in Analytical Chemistry of which he became full professor in 1993. He obtained his D.Sc. degree in separation science in 1990 and he is now at the group of analytical biosciences, Department of Pharmacy, The Faculty of Health and Medical Sciences, University of Copenhagen. His main research interests are within basic separation sciences (primarily HPLC and CE) in particular on separation mechanisms but also extended into hyphenated techniques using MS, NMR and ICP-MS besides conventional detection techniques. New techniques and methods are applied in bioanalysis and in drug metabolism. In drug metabolism focus has been on reactive drug metabolites and their possible role in idiosyncratic reactions. His is the author or co-author of more than 330 papers in international peer-review journals. For 20 years he was the President of the Scandinavien Section of The Chromatographic Discussion Group until this was changed into the Separation Sciences Foundation. He has been involved in the arrangement of a major number of national and international conferences, lately as the chair of the 26th International Symposium in Chromatography. His has been involved in administrative duties as the Head of Department of Chemistry for three years and Head of Dept. of Analytical Chemistry for six years. Furthermore his has been a member of the Board as well as of the Board of Research for the Royal Danish School of Pharmacy.
Ronald A. Hill, B.S.Chem., Ph.D., is a native of central Ohio. He graduated from the University of Michigan in 1982 with a B.S.Chem. degree, completing an honors thesis project in mechanistic organic chemistry with Professor Peter A. S. Smith. He then spent 4-1/2 years engaged in analytical chemistry and biopharmaceutics R&D at the Upjohn Company in Kalamazoo, MI, followed by graduate study at The Ohio State University, where he completed a Ph.D. in Pharmacy, with emphases in synthetic medicinal and computational chemistry. His graduate research was directed by Professors Duane D. Miller and Jan K. Labanowski (Ohio Supercomputer Ctr.). In 1991, he established a research group at ULM, mainly engaged in areas of synthetic medicinal and bioanalytical chemistry. Historically, his research, funded at various times by the NIH and the AHA, focused mostly on projects related to the central nervous system, particularly the efficient delivery of small organic molecules to the CNS and their distribution, biotransformation, and actions therein. Over the years, he also collaborated extensively with investigators working in areas of pharmaceutics, toxicology, pharmacology, and clinical sciences, and also gained extensive acumen in molecular therapeutics design, molecular biopharmaceutics, and molecular toxicology. His more-recent educational duties at the Ph.D. and Pharm.D. levels, and ongoing research collaborations in areas including cancer and Alzheimer’s disease, has demanded even more breadth and depth of knowledge, especially in areas bridging early discovery science to clinical application. He also currently serves as a member of the Expert Panel for the Cosmetic Ingredient Review, a key safety assessment body for non-drug personal care products. He has served as major adviser for a number of M.S. and Ph.D. students, and on the graduate committees of now more than 60 others, all of whom have an admirable record of accomplishment in industry, government, or academia.
Dr. Giri, is currently working as Assistant Professor at Center for Graduate Studies, West Coast University. Dr. Giri received her Bachelor of Pharmacy degree from Shri G.S Institute of Science and Technology and Master of Pharmaceutical Biotechnology from Dr. H.S. Gour University in India. She subsequently earned her PhD in Pharmaceutical Sciences from the University of Missouri-Kansas City. Her primary teaching area is pharmaceutics; her research interests include novel drug delivery, nanotechnology-based drug delivery, and mucosal delivery of microbicides. She currently serves as editorial board member and reviewer for more than five peer-reviewed scientific journals.
Novel Drug Delivery,Nano technology-Based Drug Delivery,Mucosal Delivery of Microbicides
Stuart Maudsley has been recognized as a visionary pioneer in science (both physical and biomedical) from childhood where his work was publicized on the national television program ‘The Power Game’ – a U.K. wide engineering Olympiad. Stuart has been subsequently awarded and recognized throughout his career as both an intellectual innovator and as an excellent scientist. Stuart’s primary contribution to science is in the field of receptor systems biology and pharmacotherapeutics design – within this field Stuart is one of the world’s leading young Investigators. Stuart graduated from the University of Leeds with First Class Honors in Pharmacology and was awarded the Pfizer Prize for undergraduate research. For his doctoral work Stuart was one of only 6 recipients (from a University population of 40,000) of the Universities venerated ‘Named Scholarships’, i.e. the Ackroyd, Brotherton and Brown Scholarship. After gaining his Ph.D. in Receptor Pharmacology, he was then awarded a Howard Hughes Medical Institute Fellowship Award to train with Professor Robert Lefkowitz (2012 Nobel Laureate in Chemistry) at Duke University. Following this fellowship Stuart was instantly recruited to be Principal Investigator of the Receptor Biology Section at the Medical Research Council (MRC) -Human Reproductive Sciences Unit at the University of Edinburgh. During his time at the MRC his drug discovery and development abilities was implicit in his recruitment as a scientific advisor to Ardana Bioscience Inc. where he subsequently developed a novel prostate cancer therapeutic. To broaden his already considerable biomedical experience Stuart then accepted the position of Head of the Receptor Pharmacology Unit at the National Institutes of Health (NIH-National Institute on Aging) at the Johns Hopkins University Medical Center.
Biomedical Research,Molecular Genetics